AstraZeneca announced that it has entered into a licensing agreement with Ironwood Pharmaceuticals for the exclusive US rights to Zurampic...
The FDA has approved Zurampic (lesinurad) from AstraZeneca, to treat high levels of uric acid in the blood (hyperuricemia) associated...
AstraZeneca announced that the European Commission (EC) has granted marketing authorisation for Zurampic (lesinurad) 200mg in combination with a xanthine...
AstraZeneca announced that it has entered into a licensing agreement with Grünenthal GmbH for the exclusive rights to Zurampic (lesinurad)...
AstraZeneca announced positive subanalysis data of the Phase III Zurampic (lesinurad) studies (CLEAR1, CLEAR2 and CRYSTAL) for the treatment of...
The National Institute for Health and Care Excellence has published draft guidelines preventing adults with gout from access to Zurampic...
Ironwood Pharmaceuticals has presented efficacy and safety data from two Phase III extension studies of Zurampic (lesinurad) for the treatment...
Ironwood Pharmaceuticals, Inc.has announced Duzallo (lesinurad + allopurinol) was approved by the FDA as a once-daily oral treatment for hyperuricemia...
Lesinurad (Zurampic®) is an oral selective inhibitor of the URAT1 and OAT4 uric acid (UA) transporters of the kidney, via which it inhibits UA reabsorption and thus increases renal UA excretion and lowers serum UA (sUA) levels.
Grünenthal announced that the European Commission has followed the positive opinion of the Committee for Medicinal Products for Human Use...